KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Accounts Payables (2016 - 2025)

Abbott Laboratories' Accounts Payables history spans 17 years, with the latest figure at $4.2 billion for Q4 2025.

  • For Q4 2025, Accounts Payables rose 1.07% year-over-year to $4.2 billion; the TTM value through Dec 2025 reached $4.2 billion, up 1.07%, while the annual FY2025 figure was $4.2 billion, 1.07% up from the prior year.
  • Accounts Payables for Q4 2025 was $4.2 billion at Abbott Laboratories, up from $4.1 billion in the prior quarter.
  • Across five years, Accounts Payables topped out at $4.8 billion in Q1 2022 and bottomed at $4.0 billion in Q3 2023.
  • The 5-year median for Accounts Payables is $4.2 billion (2024), against an average of $4.2 billion.
  • The largest annual shift saw Accounts Payables grew 27.82% in 2021 before it decreased 12.4% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $4.4 billion in 2021, then grew by 4.51% to $4.6 billion in 2022, then dropped by 6.77% to $4.3 billion in 2023, then fell by 2.33% to $4.2 billion in 2024, then grew by 1.07% to $4.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Accounts Payables are $4.2 billion (Q4 2025), $4.1 billion (Q3 2025), and $4.3 billion (Q2 2025).